Rimegepant - Isotope Labelled Standards
References
FAQ's
References
- Luo, Guanglin; Dubowchik, Gene M.; Macor, John E., CGRP receptor antagonists, Bristol-Myers Squibb Company, United States, US8314117B2, November 20, 2012
- Zheng, Naiyu; Zeng, Jianing; Akinsanya, Billy; Buzescu, Adela; Xia, Yuan-Qing; Ly, Van; Trouba, Kevin; Peng, Qianping; Aubry, Anne-Francoise; Arnold, Mark E., A rapid, accurate and robust UHPLC-MS/MS method for quantitative determination of BMS-927711, a CGRP receptor antagonist, in plasma in support of non-clinical toxicokinetic studies, Journal of Pharmaceutical and Biomedical Analysis Volume: 83, Pages: 237-248, 2013
Frequently Asked Questions
Can Rimegepant impurities be removed?
Depending on the impurity and its concentration, purification techniques and methods can be employed to remove or reduce them in Rimegepant.
Are there regulatory guidelines for Rimegepant impurities?
Regulatory authorities provide guidelines and limits for the level of impurities in pharmaceutical substances, including Rimegepant, to ensure product quality and safety.
What are the temperature conditions to control Rimegepant impurities?
The temperature conditions to control Rimegepant impurities typically involve storage and handling at specific temperature ranges, as specified in the drug's stability data and regulatory guidelines.
What are the temperature conditions required to store Rimegepant impurities?
Rimegepant impurities should be stored at a controlled room temperature between 2-8°C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.